[1] World health statistics 2024: monitoring health for the SDGs, Sustainable Development Goals[M]. Geneva: World Health Organization, 2024.
[2] KOUPENOVA M, CLANCY L, CORKREY H A, et al. Circulating platelets as mediators of immunity, inflammation, and thrombosis[J]. Circ Res, 2018, 122(2):337-351.
[3] TRIP M D, CATS V M, VAN CAPELLE F J, et al. Platelet hyperreactivity and prognosis in survivors of myocardial infarction[J]. N Engl J Med, 1990, 322(22):1549-1554. doi:  10.1056/NEJM199005313222201
[4] MACKMAN N. Triggers, targets and treatments for thrombosis[J]. Nature, 2008, 451(7181):914-918. doi:  10.1038/nature06797
[5] JENNINGS L K. Mechanisms of platelet activation: need for new strategies to protect against platelet-mediated atherothrombosis[J]. Thromb Haemost, 2009, 102(2):248-257.
[6] PENG B, KONG G C, YANG C, et al. Erythropoietin and its derivatives: from tissue protection to immune regulation[J]. Cell Death Dis, 2020, 11(2):79. doi:  10.1038/s41419-020-2276-8
[7] LEONG D P, MCMURRAY J J V, JOSEPH P G, et al. From ACE inhibitors/ARBs to ARNIs in coronary artery disease and heart failure(part 2/5)[J]. J Am Coll Cardiol, 2019, 74(5):683-698. doi:  10.1016/j.jacc.2019.04.068
[8] QI Z Y, HU L, ZHANG J J, et al. PCSK9(proprotein convertase subtilisin/kexin 9)enhances platelet activation, thrombosis, and myocardial infarct expansion by binding to platelet CD36[J]. Circulation, 2021, 143(1):45-61. doi:  10.1161/CIRCULATIONAHA.120.046290
[9] CHEN Y F, FU W R, ZHENG Y B, et al. Galectin 3 enhances platelet aggregation and thrombosis via Dectin-1 activation: a translational study[J]. Eur Heart J, 2022, 43(37):3556-3574. doi:  10.1093/eurheartj/ehac034
[10] CHEN Y F, HONG J, ZHONG H X, et al. IL-37 attenuates platelet activation and thrombosis through IL-1R8 pathway[J]. Circ Res, 2023, 132(9):e134-e150.
[11] LI Z Y, ZHENG S L, WANG P, et al. Subfatin is a novel adipokine and unlike Meteorin in adipose and brain expression[J]. CNS Neurosci Ther, 2014, 20(4):344-354. doi:  10.1111/cns.12219
[12] LI Z Y, SONG J, ZHENG S L, et al. Adipocyte metrnl antagonizes insulin resistance through PPARγ signaling[J]. Diabetes, 2015, 64(12):4011-4022. doi:  10.2337/db15-0274
[13] QI Q, HU W J, ZHENG S L, et al. Metrnl deficiency decreases blood HDL cholesterol and increases blood triglyceride[J]. Acta Pharmacol Sin, 2020, 41(12):1568-1575. doi:  10.1038/s41401-020-0368-8
[14] LI Z Y, FAN M B, ZHANG S L, et al. Intestinal Metrnl released into the gut lumen acts as a local regulator for gut antimicrobial peptides[J]. Acta Pharmacol Sin, 2016, 37(11):1458-1466. doi:  10.1038/aps.2016.70
[15] BAHT G S, BAREJA A, LEE D E, et al. Author Correction: Meteorin-like facilitates skeletal muscle repair through a Stat3/IGF-1 mechanism[J]. Nat Metab, 2020, 2(8):794. doi:  10.1038/s42255-020-0257-y
[16] REBOLL M R, KLEDE S, TAFT M H, et al. Meteorin-like promotes heart repair through endothelial KIT receptor tyrosine kinase[J]. Science, 2022, 376(6599):1343-1347. doi:  10.1126/science.abn3027
[17] ZHENG S L, LI Z Y, SONG J, et al. Endothelial METRNL determines circulating METRNL level and maintains endothelial function against atherosclerosis[J]. Acta Pharm Sin B, 2023, 13(4):1568-1587. doi:  10.1016/j.apsb.2022.12.008
[18] DADMANESH M, AGHAJANI H, FADAEI R, et al. Lower serum levels of Meteorin-like/Subfatin in patients with coronary artery disease and type 2 diabetes mellitus are negatively associated with insulin resistance and inflammatory cytokines[J]. PLoS One, 2018, 13(9):e0204180. doi:  10.1371/journal.pone.0204180
[19] LIU Z X, JI H H, YAO M P, et al. Serum Metrnl is associated with the presence and severity of coronary artery disease[J]. J Cell Mol Med, 2019, 23(1):271-280. doi:  10.1111/jcmm.13915
[20] MIAO Z W, WANG N, HU W J, et al. Chronic vascular pathogenesis results in the reduced serum Metrnl levels in ischemic stroke patients[J]. Acta Pharmacol Sin, 2024, 45(5):914-925. doi:  10.1038/s41401-023-01204-5
[21] 缪朝玉, 郑斯莉, 缪竹威, 等. Metrnl抗血栓用途. 中国: 201710778140.5 [P]. 2017-09-01.
[22] TIEDT R, SCHOMBER T, HUI H S, et al. Pf4-Cre transgenic mice allow the generation of lineage-restricted gene knockouts for studying megakaryocyte and platelet function in vivo[J]. Blood, 2007, 109(4):1503-1506. doi:  10.1182/blood-2006-04-020362
[23] CALAMINUS S D, GUITART A V, SINCLAIR A, et al. Lineage tracing of Pf4-Cre marks hematopoietic stem cells and their progeny[J]. PLoS One, 2012, 7(12):e51361. doi:  10.1371/journal.pone.0051361
[24] PERTUY F, AGUILAR A, STRASSEL C, et al. Broader expression of the mouse platelet factor4-cre transgene beyond the megakaryocyte lineage[J]. J Thromb Haemost, 2015, 13(1):115-125. doi:  10.1111/jth.12784